Investigators are using health-related quality of life measures more and more in controlled clinical trials, including trials in patients with heart faihue. The purpose of this report is to provide a basic introduction to the measurement properties necessary for adequate measurement of health-related quality of life and the available approaches for such measurement and to introduce examples of health-related quality of life measurement in patients with heart failure. This review is not intended as a detailed update on the health-related quality of life studies. The interested reader will find more extensive reviews (1-3) available elsewhere.
approach lies in its potential for increased responsiveness, which may result from including only important aspects of health-related quality of life that are relevant to the patients being studied. The instrument may be specific to the disease (instruments for chronic lung disease [17] or asthma [If!]), specific to a population of patients (instruments designed to measure the health-related quality of life of the elderly, who may be a&ted with a wide variety of ditferent diseases, specific to a certain function (questionnaires that examine emotional or sexual function) or specific to a given condition or problem (such as pain) that may be caused by a variety of underlying pathologic conditions.
Claims about health-related quality of Me may be based on questionnaires with diverse content. Investigators need to review in detail the content of questionnaires they are considering using to ensure that the areas they wish to target are covered. This highlights an advantage of many specific measures that relate closely to areas routinely explored by the physician. The disadvantages of specific measures are that they are (deliberately) not comprehensive and cannot be used to compare across conditions. They are designed to focus on elements specific to a target condition and therefore do not measure drug toxicity and certainly will not detect unforseen side effects unrelated to manifestations of the target condition. They are also less likely than generic measures to have carefully considered the relative values of individual questions or domains within the questionnaire, and the typical approach is to weight items equally.
Specific instruments for heart failure have been used in several randomized trials and represent the approach to healthrelated quality of life measurement in heart failure that has to date been most frequently applied. The remainder of this review wiil provide examples of ho* speci% health-relatuzd quality of life measures have been used in clinical trials in heart failure. Before moving to these examples, however, 1 will briefly discuss issues of questionnaire administration.
Questionnaire Administration
The history of heaith-related quality of life measurement in clinical trials is strewn with failures caused by inadequate attention to compliance and administration. The principles of use of questionnaires to ensure optimal performance include the following. 1. Recognition of hnportauce. If investigators treat questionnaires as minor additions to a protocol, they can be assured that compliance will be poor and missing and inaccurate data common. Health-related quality of life questionnaire administration must have the same priority as, for instance, measurement of hypertension within a trial examining medication to lower blood pressure.
2. Training Inte&ewers. Interviewers, or those supervising self-administered instruments, must be properly trained. Important principles include rigid adherence to modes and wordii of instructions and avoiding bias in administration that may arise through explanations that suggest that some responses are more appropriate than others and through verbal and nonverbal expressions of approval or disap proval.
3. MonitAng. Even after adequate training, interviewers can easily go astray. Trials must include monitoring mechanisms to ensure adherence to principles of questionnaire administration.
Disease-Specific Measures in Heart Failure
The Chronic Heart Failure Questionnaire. I wiIl use the example of our own instrument to illustrate how diieasespecific measures can be developed and tested in the setting of controlled clinical trials. We began by constructing a list of items likely to be important to patients with heart fa&e (19). The items were generated through a review of pub lished reports, consultation with cardiac nurse specialists and cardiologists and unstructured interviews with patients. The final Item Selection Questionnaire contained I23 items, of which 61 dealt primarily with physical function and 62 with emotional or social function. This questionnaire was administered to 88 patients with a clinical diagnosis cf heart failure supported by echocardiographic, angiographic or radionuclide angiographic evidence of cardiac dysfunction. The patients were asked if the 123 items represented ways in which their lives were affected by their heart problem.
Patients rated the importance of each atlirmatively answered item on a 5-point scale. We chose the items that were most frequentiy labeled as problems and were most important for the final Chronic IIeart Failure Questionnaire. The items feU into three domains: dyspnea, fatigue and emotional function.
In the dyspnea domain, we found that the items chosen varied widely depending on the patient's gender, range of activities and level of disability. In the Chronic Heart Failure Questionnaire, therefore, we ask patients to choose the five activities associated with shortness of breath that they do frequently and are most important in their daily lives. Over the course of a study, we repeatedly ask patients the extent of their dyspnea in those five activities. Items on each of the three domains are presented as 7-point scales.
Studies (20) of Chronic Heart Failure Questionnaire measurement properties took place within a study of digoxin in patients with heart failure. Patients in sinus rhythm with echocardiographic evidence of left ventricular dysfunction and significant functional disability participated in a doubleblind randomized trial in which they were then given digoxin and an identical placebo, each for 7 weeks, the order determined by random allocation. Visits were planned for the end of weeks 3,s and 7 of each treatment period, but if a patient's condition deteriorated, the period was terminated prematurely and outcome measures were obtained. Measures of outcome included a clinica! heart failure score (including findings from history, physical examination and chest radiograph) (21), a 6-mitt walk test @2), the Chronic Heart Failure Questionnaire, global ratings of change in dyspnea, Mgue and emotional function, the Specific Activ- The study showed digoxin to be of benefit. Seven patients required a shortened study period because of increas@ hesrt fhilure; ail seven treatment failures occurred while patients were takii piacebo (p = 0.016). The Chronic Heart Failure Questionnaire showed trends favoring digoxin that were found in all three domains (Table 1) . However, the digoxin-imluced cbanqes in dyspnea were small, and the changes in Mque and emotional function were very small. Qnly for the dyspnea domain did the dil%erence between digoxin and placebo reach conventional levels of stutisticai si@ftcance. The resuits suguest two possible conclusions. 1) Digoxin didnotmakeanydiiferenceinfatiqueandemotionalfunction (and only a small dikence in dyspnea), or 2) diiuin hadanimpormnteifectthattheChronicHeartFailure Question&e Med to detect. To elucidate this issue, we examined changes in scores in subjects whose giobai raw ofchange sugqested improvement or deterioration between study visits, kespeck of the treatment they were teceiving. If the Chronic Heart Faiiure Questionnaire is responsive, one would anticipate an improvement in score that would be statisticaily &u&ant. For example, 11 of the 20 subjects reported au improvement in their giobai rat& of dyspnea at some time during the study (Table 2) 2. Change in Chronic Heart Faiiurc Questionnaitc dyspnea score should relate closely (r 2 0.5) to change in waik test score. The correlation observed was 0.60.
3. Change in Chronic Heart Fake Questionnaire dyspnea score should bear a moderak correlation (r > 0.4) with change in heart failure score. The correlation observed was 0.42.
The strong coneiations support the validity of the questionnaire. Additionai support is provided by the gradient of conelation: sttwnger correlations for measures more closely tied to functionai capacity, a weaker correlation with the heart ihike score, which rellects the ciinician's assessment.
It wouid be worthwhiie lulowing how other functional status measures used in patients with heart failure compare with the Chumic Heart Failure Questionnaire. Because the New Yotit Heart Associatk and Specik Activity Scale provide measures of dyspuea during daily activity in patients withheart&ilute,the~comparisoniswiththe Chronic Heart Failure Questionnaire dyspnea score, and if these other instruments are valid, then predictions mgardii Chronic Heart Failure Question&e dyspnea score should also apply. Correlations between changes in Chronic Heart Failme Questionnaire dyspnea score, the New York Heart AssociatioufimctionalciassandtheSpeciiActivityScale ontheonehand,aodglobelratingofc~indyspnea, chatqgeinwalktestscoreandchangeinheartfaiiutcscomon the other, are shown in gesting that the former is a more valid measure of changes in shortness of breath in patients with heart failure.
Other speelile hMrumentx Ru heart fallure. The Chronic Heart Failure Questionnaire is not the only disease-specific health-related quality of ltie measure that has been used in clinical trials in heart failure. 
